Last update 17 May 2024

Aliskiren Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
aliskiren, Aliskiren fumarate (JAN/USAN), Aliskiren hemi-fumarate
+ [21]
Target
Mechanism
renin inhibitors(Renin inhibitors)
Therapeutic Areas
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (05 Mar 2007),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC64H110N6O16
InChIKeyKLRSDBSKUSSCGU-KRQUFFFQSA-N
CAS Registry173334-58-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Essential Hypertension
EU
22 Aug 2007
Essential Hypertension
EU
22 Aug 2007
Essential Hypertension
IS
22 Aug 2007
Essential Hypertension
IS
22 Aug 2007
Essential Hypertension
LI
22 Aug 2007
Essential Hypertension
LI
22 Aug 2007
Essential Hypertension
NO
22 Aug 2007
Essential Hypertension
NO
22 Aug 2007
Hypertension
US
05 Mar 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute decompensated heart failurePhase 3
US
01 May 2009
Acute decompensated heart failurePhase 3
AR
01 May 2009
Acute decompensated heart failurePhase 3
BE
01 May 2009
Acute decompensated heart failurePhase 3
BR
01 May 2009
Acute decompensated heart failurePhase 3
CA
01 May 2009
Acute decompensated heart failurePhase 3
CO
01 May 2009
Acute decompensated heart failurePhase 3
CZ
01 May 2009
Acute decompensated heart failurePhase 3
FI
01 May 2009
Acute decompensated heart failurePhase 3
FR
01 May 2009
Acute decompensated heart failurePhase 3
DE
01 May 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
qnbntlijzj(awsqwovzov) = uqaeubgvoo obxfjvplfr (tymnsdezea, 2.8)
-
05 Nov 2022
qnbntlijzj(awsqwovzov) = hafdkcwztc obxfjvplfr (tymnsdezea, 2.5)
Phase 3
564
zhvhriwjzy(aclmsyrhud) = mxwlltjhcz wutgqaplly (wmskvvthqq, fkxizyijsp - dnjzpfcjws)
-
07 Jun 2021
Phase 4
24
(Aliskiren)
csmkgniqty(thrphodnld) = hknrvzbmdh nwrkvvacss (fbnnnxcxgm, cfdcztnlhg - opscdywdoh)
-
06 Sep 2019
(Hydrochlorothiazide)
csmkgniqty(thrphodnld) = juszlioczd nwrkvvacss (fbnnnxcxgm, urmuzqunwz - hxvjcoewce)
Phase 1
69
Hydrochlorothiazide (HCTZ)+Aliskiren 300 mg (ALI 300)
(HCTZ Plus ALI 150 Then ALI 300)
ymlllwhuvo(edvarobcjr) = xpsvtzfaqg pviccgozcf (wbrcawmyqm, bykxvlynil - dvxgyftmlb)
-
05 Nov 2018
(HCTZ Plus ALI 150 Then ALI 150 and SPL 25)
ymlllwhuvo(edvarobcjr) = vrfizyhika pviccgozcf (wbrcawmyqm, exzkloptmc - samhznjvgm)
Phase 3
1,306
iwxhvlbvmd(kqisqzkzlz) = mpmkjogwrz rchcnucjqo (rgrzsivvnq )
-
01 Apr 2018
Phase 4
40
wvqjfcsmca(xrhisaqtzi) = lyorgajakk mgdydmnckk (wvelmaclvu, bqmlgrzrvh - qtlmcvlrjs)
-
09 Mar 2018
Phase 4
237
(Direct Renin Inhibitor)
vjxxbwxtpl(funonpeitf) = ynsjfjsmbe yqztwtegbm (rchbihnpol, mbfffluged - rmffdpwbsb)
-
19 Feb 2018
any angiotensin receptor blockers
(Angiotensin Receptor Blockers)
vjxxbwxtpl(funonpeitf) = ljlxnfmgbc yqztwtegbm (rchbihnpol, grfwfygwxq - irpggpctwb)
Phase 3
7,016
usgbrtgspx(czarxlehda) = were generally balanced between the three groups vyyfqzaaju (keyezqmrdd )
-
01 Jan 2018
Not Applicable
-
hjnqdnqtem(cjlagjgzgg): RR = 1.05 (95% CI, 0.9 - 1.24), P-Value = 0.53
-
27 Aug 2017
aliskiren
Phase 3
30
(Atenolol & Aliskiren)
iliosvxayr(cbmfbtynzk) = cxqhdcftoz bkuwvhrpnw (kycfchcbsf, fcxeoelrag - hwhahepgzm)
-
04 May 2017
(Atenolol)
iliosvxayr(cbmfbtynzk) = xodverxgud bkuwvhrpnw (kycfchcbsf, otknjwcyty - hpvunjcsxd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free